Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.

The authors demonstrated previously that the combination of topotecan (TPT) and carboplatin (CBP) was more effective than current chemotherapeutic combinations used to treat retinoblastoma in an orthotopic xenograft model. However, systemic coadministration of these agents is not ideal, because both agents cause dose-limiting myelosuppression in children.
To overcome the toxicity associated with systemic TPT and CBP, the authors explored subconjunctival delivery of TPT or CBP in an orthotopic xenograft model and in a genetic mouse model of retinoblastoma (Chx10-Cre;Rb(lox/lox);p107(-/-);p53(lox/lox)). The effects of combined subconjunctival CBP (CBP(subcon)) and systemic TPT (TPT(syst)) were compared with the effects of combined TPT(subcon) and CBP(syst.) at clinically relevant dosages.
Pharmacokinetic and tumor-response studies, including analyses of ocular and hematopoietic toxicity, revealed that CBP(subcon)/TPT(syst) was more effective and had fewer side effects than TPT(subcon)/CBP(syst).
For the first time, retinoblastoma was ablated and long-term vision was preserved in a mouse model by using a clinically relevant chemotherapy regimen. These results eventually may be translated into a clinical trial for children with this debilitating cancer.
AuthorsKatie M Nemeth, Sara Federico, Angel M Carcaboso, Ying Shen, Paula Schaiquevich, Jiakun Zhang, Merrill Egorin, Clinton Stewart, Michael A Dyer
JournalCancer (Cancer) Vol. 117 Issue 2 Pg. 421-34 (Jan 15 2011) ISSN: 0008-543X [Print] United States
PMID20818652 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 American Cancer Society.
Chemical References
  • Topotecan
  • Carboplatin
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Carboplatin (administration & dosage, adverse effects, pharmacokinetics)
  • Cell Line, Tumor
  • Conjunctiva
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Rats
  • Retinal Neoplasms (drug therapy)
  • Retinoblastoma (drug therapy)
  • Topotecan (administration & dosage, adverse effects, pharmacokinetics)
  • Visual Acuity
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: